More than 200 naturally occurring mutations have been identified in the human CaSR, which have been linked to diseases involving dysregulation of extracellular Ca 2ϩ homeostasis. These mutations have classically been termed "loss-" or "gain-of-function" mutations, which is an oversimplification given that amino acid changes can alter numerous molecular properties of a receptor. We thus sought to characterize the effects of 21 clinically relevant mutations, the majority located in the heptahelical domains and extracellular loop regions of the CaSR, using flow cytometry to measure cell surface receptor expression levels, and measurements of intracellular Ca 2ϩ mobilization and ERK1/2 phosphorylation to monitor receptor signaling. We identified distinct molecular phenotypes caused by these naturally occurring amino acid substitutions, which included combinations of loss-and gain-of-expression and changes in intrinsic signaling capacity. Importantly, we also identified biased signaling in the response of the CaSR to different mutations across the two pathways, indicating that some mutations resulted in receptor conformations that differentially altered receptor-coupling preferences. These findings have important implications for understanding the causes of diseases linked to the CaSR. A full appreciation of the molecular effects of these amino acid changes may enable the development of therapeutics that specifically target the molecular determinant of impairment in the receptor. ; ECL, extracellular loop; FBS, fetal bovine serum; FHH, familial hypocalciuric hypercalcemia; GPCR, G protein-coupled receptor; HHD, heptahelical domain; IP, inositol phosphate; NSHPT, neonatal severe hyperparathyroidism; TM, transmembrane; VFT, venus fly trap; WT, wild type.
have classically been termed "loss-" or "gain-of-function" mutations, which is an oversimplification given that amino acid changes can alter numerous molecular properties of a receptor. We thus sought to characterize the effects of 21 clinically relevant mutations, the majority located in the heptahelical domains and extracellular loop regions of the CaSR, using flow cytometry to measure cell surface receptor expression levels, and measurements of intracellular Ca 2ϩ mobilization and ERK1/2 phosphorylation to monitor receptor signaling. We identified distinct molecular phenotypes caused by these naturally occurring amino acid substitutions, which included combinations of loss-and gain-of-expression and changes in intrinsic signaling capacity. Importantly, we also identified biased signaling in the response of the CaSR to different mutations across the two pathways, indicating that some mutations resulted in receptor conformations that differentially altered receptor-coupling preferences. These findings have important implications for understanding the causes of diseases linked to the CaSR. A full appreciation of the molecular effects of these amino acid changes may enable the development of therapeutics that specifically target the molecular determinant of impairment in the receptor. T he human calcium-sensing receptor (CaSR) is a Family C G protein-coupled receptor (GPCR) that is ubiquitously expressed in tissues including parathyroid cells and thyroid calcitonin-producing parafollicular cells (C cells), kidney, intestine, bone, and brain (1, 2) . It functions predominantly in the maintenance of systemic calcium homeostasis and plays a pivotal role in parathyroid hormone secretion, kidney function, bone mineralization and turnover, regulation of intestinal fluid secretion, and turnover of intestinal epithelial cells (1) (2) (3) (4) (5) (6) . These functions are achieved upon binding of different endogenous orthosteric ligands, specifically Ca 2ϩ and Mg 2ϩ , as well as allosteric ligands, such as L-amino acids and ␥-glutamyl peptides, which all interact with the receptor's large N-terminal "venus fly trap" (VFT) domain. More than 200 mutations have been identified in the CaSR, and many result in disorders including autosomaldominant hypocalcemia and Bartter syndrome type V, caused by gain-of-function mutations, and familial hypocalciuric hypercalcemia (FHH), familial benign hypercalcemia, and neonatal severe hyperparathyroidism (NSHPT), which result from loss-of-function mutations. These disorders are characterized by disturbances of extracellular Ca 2ϩ (Ca vere salt wasting arises from impaired renal NaCl reabsorption in the thick ascending limb of the loop of Henle. The classification of mutations as loss-or gain-of-function is generally based upon the observed clinical manifestations with regard to Ca 2ϩ o concentrations, and in some instances, upon the ability of Ca 2ϩ o to activate these mutant CaSR. However, classifying such CaSR amino acid mutations as loss-or gain-of-function is a mechanistic oversimplification, because mutations can modify a number of distinct molecular properties of a GPCR, each with different implications for pharmacotherapeutic interventions. For instance, mutations can affect the binding affinity of an agonist for its receptor, either directly through disruption of the ligand-binding pocket (7) , or indirectly via stabilization of a specific conformational state (8) . Alternatively, mutations may affect the coupling of a receptor to its intracellular signaling components (9) , manifested as changes in ligand signaling efficacy. Some alterations in receptor-coupling efficiency are reflected by changes in agonist-dependent desensitization, leading to either diminished or enhanced down-regulation of receptor signaling (10); others alter the basal (constitutive) activity of the receptor, as documented for various GPCR (11) (12) (13) including the CaSR (14, 15) . Finally, mutations can affect the ability of a receptor to fold efficiently and traffic to the cell surface, thereby reducing the number of receptors that are exposed to endogenous agonists and impairing receptor signaling (16 -22) . Indeed, numerous mutations identified to date reduce the ability of the CaSR to traffic to the cell surface (23) and may thus cause FHH and related hypercalcemic disorders. Conversely, mutations may cause gain-of-expression and subsequent increase in stimulus-response coupling. Thus, naturally occurring mutations may result in a multitude of effects, ranging from subtle alterations in signaling to complete misfolding of the protein, all as a consequence of altered receptor conformation.
An emergent paradigm in GPCR biology that is directly linked to the conformational state of the receptor is the phenomenon of biased signaling, also known as "stimulus bias," "functional selectivity," or "ligand-directed trafficking of receptor stimulus" (24) , which refers to the capacity of different ligands to select distinct conformational states at the expense of others. In turn, this raises the possibility of cell-or tissue-specific signaling profiles that vary in a ligand-specific manner. Biased signaling has recently been demonstrated for the CaSR (25, 26) . However, to date, it is not known how biased signaling by the CaSR is affected by different types of naturally occurring mutations, even though this has important implications for the mechanistic basis of the associated genetic disorders and for the outcome of exogenously administered ligands.
The aim of the current study was to understand how clinically relevant CaSR mutations cause changes in protein function and whether these changes may also induce biased signaling. We chose specifically to focus on amino acids that are located in the transmembrane heptahelical domain (HHD) and extracellular loops (ECL) because these regions are important for the actions of small molecule ligands (27) and may thus have a direct impact on therapeutic utility. We reveal that these mutations result in hitherto unappreciated effects, yielding distinct molecular phenotypes and alterations in signal bias.
Materials and Methods
DMEM, blasticidin S HCl, and fetal bovine serum (FBS) certified to contain less than 10 ng/ml tetracycline were obtained from Invitrogen (Carlsbad, CA), whereas hygromycin B was from Roche (Mannheim, Germany). The Flp-In T-REx human embryonic kidney 293 cells and Fluo-4 AM (acetoxymethyl ester) were purchased from Invitrogen. AlphaScreen SureFire streptavidin donor, anti-IgG (Protein A) acceptor beads and UltimaFlo AF scintillation fluid were purchased from PerkinElmer (Wellesley, MA), whereas all other ERK1/2 phosphorylation assay reagents were a kind gift from TGR Biosciences (Adelaide, Australia). Inositol-free DMEM was from MP Biomedicals (Seven Hills, Australia), AG1-X8 anion exchange formate-form resin from Bio-Rad Laboratories (Hercules, CA) and Multiscreen HTS-BV filter plates from Millipore (Kilsyth, Australia). All other chemicals were from Sigma Chemical Co. (St Louis, MO).
Cell culture
Briefly, the human wild-type (WT) CaSR cDNA sequence was amplified from pcDNA 3.1ϩ using standard PCR techniques and cloned using Gateway technology (Invitrogen). Site-directed mutagenesis was performed on the WT cDNA to insert a c-myc tag in the VFT region of the CaSR using MultiQuickchange site-directed mutagenesis as described previously (25) . The CaSR with the c-myc tag was subsequently transferred into pcDNA5/frt/TO (Invitrogen) and QuikChange II Site-Directed Mutagenesis (Stratagene, La Jolla, CA) was used according to the manufacturer's instructions to change the amino acid residues using primers listed in Supplemental Table 1 published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org.
For the generation of stable cell lines expressing the WT CaSR and the mutated receptors, Flp-In TREx human embryonic kidney 293 cells were transfected in conjunction with the pOG44 Flp-recombinase expression vector (Invitrogen) using standard lipofection transfection methods. Cells expressing the appropriate constructs were selected using 200 g/ml hygromycin B and 5 g/ml blasticidin S HCl.
After selection, cells were grown and maintained in DMEM containing 10% certified FBS, 200 g/ml hygromycin B, and 5 g/ml blasticidin S HCl, whereas untransfected cells were maintained in DMEM containing 10% FBS. For harvesting, cells were detached from tissue culture flasks using PBS solution (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ) supplemented with 2 mM EDTA. Cells were then centrifuged at 350 ϫ g for 10 min and resuspended in media.
Flow cytometry analysis for receptor expression
Cells were seeded in a 96-well plate at a density of 100,000 cells per well with or without 100 ng/ml tetracycline. The next day, cells were harvested with PBS supplemented with 0.1% BSA, 2 mM EDTA, and 0.05% Na Azide (washing buffer) and transferred to wells of a 96 well v-bottom plate, centrifuged for 3 min at 350 ϫ g at 4 C, and resuspended in 100 l blocking buffer (PBS, 5% BSA, 2 mM EDTA, and 0.05% Na Azide). Cells were incubated for 30 min in blocking buffer and subsequently incubated for 1 h with an anti-c myc mouse antibody (either from Sigma or made in house), diluted in blocking buffer at 1 g/ml. Cells were subsequently washed with washing buffer and incubated for 1 h with either Alexa Fluor 488 or phycoerythrinconjugated antimouse antibody (Molecular Probes, Inc., Eugene, OR; Invitrogen) diluted in washing buffer containing 5 nM Sytox Red (Molecular Probes, Invitrogen). After one wash, cells were resuspended in washing buffer, and the fluorescence signal was quantified using a FACS Calibur.
Ca

2؉ i mobilization assays
Cells were seeded in a clear 96-well plate coated with poly-D-lysine (50 g/ml) at 100,000 cells per well and incubated overnight in the absence or presence of 100 ng/ml tetracycline. The following day, cells were washed with 200 l assay buffer (150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl 2 , 10 mM D-Glucose, 10 mM HEPES, 0.1 mM Ca 2ϩ o , 0.5% BSA, and 4 mM probenecid at pH 7.4) and loaded with 100 l Fluo-4 AM (1 M) for 1 h at 37 C. Cells were washed again with 200 l assay buffer before the addition of fresh assay buffer. The release of Ca 2ϩ i was measured using a Flexstation 1 or 3 (Molecular Devices; Sunnyvale, CA). Fluorescence was detected for 60 sec at 485 nm excitation and 525 nm emission. Relative fluorescence units were normalized to the fluorescence stimulated by ionomycin to account for differences in cell number and loading efficiency and further normalized to the maximum response observed for the WT CaSR.
ERK1/2 phosphorylation assays
Cells were seeded at 100,000 cells per well into a poly-Dlysine-coated (50 g/ml) transparent 96-well plate and grown overnight with or without tetracycline. The following day, cells were washed twice with PBS and serum-free DMEM containing 16 mM HEPES, and 0.1 mM Ca 2ϩ o was added to wells. Ca 2ϩ o was added to wells and incubated for 2.5 min (the time determined in prior assays for ERK1/2 phosphorylation to peak). All other details are as described previously (28) .
Inositol phosphate (IP) accumulation assays
Cells were seeded at 100,000 cells per well into a poly-Dlysine-coated (50 g/ml) transparent 96-well plate and incubated overnight in inositol-free DMEM supplemented with 10% certified FBS, 100 ng/ml tetracycline, and myo- [2- 3 H]inositol at 1 Ci/well. The following day, the media was aspirated, and cells were washed twice with assay buffer (150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl 2 , 10 mM D-Glucose, 10 mM HEPES, 0.1 mM Ca 2ϩ o and 0.5% BSA at pH 7.4). Assay buffer (100 l) supplemented with 10 mM LiCl were added to each well, and cells were incubated at 37 C for 20 min. Aliquots (50 l) of concentrated agonist diluted in buffer containing 10 mM LiCl were then added to each well and incubated at 37 C for 30 min. Formic acid (50 l; 400 mM) was added to each well, and plates were frozen at Ϫ80 C and defrosted at 45 C. This freeze/thaw cycle was repeated once more. Wells of a multiscreen HTS-BV filter plate were packed with anion exchange formate form resin, and 200 l 100 mM formic acid were added to the resin and incubated for at least 5 min at room temperature. Formic acid was drawn through the resin using a vacuum manifold (Millipore), and the resin was washed five times with 100 l dH 2 0. Cell lysates were loaded onto the resin and incubated at room temperature for at least 5 min and once again drawn through the resin using a vacuum manifold. Elution buffer (75 l) (1 M ammonium formate dissolved in 100 mM formic acid) was then added to resin and incubated for at least 5 min before drawing the eluate into a 96-well plate. This was repeated once more. Eluate (100 l ) was transferred into wells of a 96-well isoplate (PerkinElmer), and 150 l UltimaFlo AF scintillation fluid were added to wells. Plates were incubated at room temperature until the eluate/scintillation fluid mixture went clear (ϳ4 h), and radioactivity was determined by liquid scintillation counting on a Microbeta counter (PerkinElmer).
Data analysis
Data were analyzed with GraphPad Prism (version 5.03; GraphPad Software, San Diego, CA). All parametric measures of potency, affinity, and cooperativity were estimated as logarithms (64) . Data of the functional CaSR concentration-response curves obtained were fitted to the following four-parameter concentration response-curve equation
where E is the response, Basal and E max represent the bottom and top asymptotes of the curve, respectively, [C] denotes the ambient agonist (Ca A one-way ANOVA with a Dunnett's post test was used to determine statistical differences (P Ͻ 0.05) between pEC 50 and Hill slope (nH) values at the WT and mutant CaSR. For significant differences in E max values and for expression studies, data were transformed to the percent of the WT CaSR E max or expression (WT being 100%); thus differences between the WT and mutant receptors were considered significant when the 95% confidence interval fell outside 100%.
To construct the Bias Plots shown in Fig. 5 , the responses to equimolar concentrations of Ca . If the agonist showed no preference for one pathway over another, the concentration-response curves would be coincident, and the bias plot data points would overlap with the line of identity. If, however, the receptor couples more strongly to one pathway over another, the points will fall either side of this line toward the preferred pathway.
Results
Rationale for choice of naturally occurring mutations
We selected 20 loss-or gain-of-function mutations (Supplemental Fig. 1 Q, because this mutation has been linked to NSHPT in heterozygous patients (53) (54) (55) and was thus used as a comparative, well-studied, mutant that is located outside the HH/ECL domains of the receptor.
Mutations in the HH domains of the human CaSR cause alterations in cell surface receptor expression
A tetracycline-inducible recombinant expression system was used to control receptor density, with 100 ng/ml tetracycline promoting robust expression of the CaSR (referred to herein as "tetracycline-induced" conditions). The main effects of tetracycline were to increase the number of cells that expressed the receptor of interest and to enhance receptor expression in each cell (Supplemental Fig. 2 Fig. 2A) without substantial changes in cell surface expression (Fig. 1) .
The second phenotype was demonstrated by two different amino acid substitutions at residue R 680 . R 680 C and R 680 H substitutions caused the cell surface expression to be reduced by more than 90% in comparison with the WT CaSR but the intrinsic signaling capacity of these receptors was not altered (Fig. 2B ). This was confirmed by determination of the signaling of the WT CaSR expressed at a similar level to the R 680 C and R 680 H mutant receptors, achieved by removing tetracycline (referred to herein as "noninduced" conditions). Under such noninduced conditions, the expression of the WT CaSR was reduced by approximately 80%, and its Ca 2ϩ o potency and maximal response were significantly decreased (P Ͻ 0.05) compared with that determined in the presence of tetracycline (Table 1) . This highlights how alterations in receptor expression levels can lead to changes in stimulus-response coupling, which may be observed as a change in the agonist potency and/or maximal response. Thus, Ca 2ϩ o potency at the noninduced WT CaSR expression level was very similar to that observed at the R 680 C and R 680 H mutants. The small reductions in the maximum responses of these mutants were likely due to their slightly lower expression than the noninduced WT CaSR (Table 1) . Collectively, these results suggest that the loss of function of these two mutants can be attributed to reductions in cell surface expression and not to any attenuation of their intrinsic signaling capacity. It must be noted that for many of the mutants, including R 680 C and R 680 H, a change in the Hill slope of the agonist concentration-response curve was observed (Tables 1 and 2 ). These changes were not directly related to alterations in signaling capacity of the receptors, because although a reduction in Hill slope (i.e.
FIG. 1.
Naturally occurring mutations in the CaSR cause alterations in receptor expression levels. Effects of CaSR mutations on the expression level of the receptor. Expression was induced overnight with 100 ng/ml tetracycline and analyzed the following day using flow cytometry. Bars represent means ϩ SEM fluorescence from the cell population determined from at least three independent experiments. Statistical significance was defined where the 95% confidence interval did not include 100% (i.e. WT CaSR expression). shallowing of the curve) was observed for many of the loss-of-function mutants, no such change was observed at the V 817 I receptor. Conversely, even some gain-of-function mutants exhibited a reduction in Hill slope. Thus, although the R 680 C and R 680 H mutants have been classified as pure loss-of-expression mutants, there may be an unappreciated effect of these mutations, and others, on an alternative functional property of the receptor that was not studied herein, such as its ability to form higher order oligomers, which may indeed alter the number of agonistbinding sites and subsequent cooperativity within the oligomer.
In the case of the third phenoype, M 734 R and G 778 D mutants, no Ca 2ϩ i mobilization signal was detected (Fig.  2C) ; therefore, the loss of activity likely arises from both the loss of expression and a loss of intrinsic signaling capacity. Finally, a fourth phenotype was observed for the mutants S 657 Y, G 670 E, and G 670 R (Fig. 2D) . Their cell surface expression was also significantly reduced under tetracycline-induced conditions, but the Ca 2ϩ o potency at these three mutants was significantly greater than at the WT CaSR expressed at similar levels (i.e. under noninduced conditions). There was a small reduction in the maximum response of S 657 Y but this was likely due to its 2-fold lower expression than the noninduced WT CaSR. Thus, at the level of the receptor itself, this last set of mutants was not loss-of-function, but gain-of-function with reduced expression. L were not reduced with respect to WT. Second, it may have arisen from a reduction in intrinsic signaling capacity. This would imply a concomitant gain in agonist affinity, which was excluded by the demonstration that agonist potency was not enhanced uniformly across signaling pathways (see ERK1/2 phosphorylation assays below). The third and most likely explanation for the reduction in maximal response is enhanced desensitization of the Ca mobilization assays in the current study, presumably because constitutive receptor activity depletes Ca 2ϩ i stores and, in turn, attenuates agonist-induced Ca 2ϩ i mobilization. Inositol phosphate accumulation assays, performed as an alternative measure of G␣ q -mediated signaling, confirmed that there was a high degree of constitutive receptor signaling for A 843 E (Supplemental Fig. 3 ).
Mutations in the human CaSR induce pathwayselective signaling bias
To assess whether the effects of naturally occurring mutations were common to all signaling responses, or whether there was an element of bias in sensitivity to the mutations, a second signaling pathway was examined. In addition to G␣ q , G␣ i/o G proteins are important for the control of PTH release (57) . Thus, phosphorylation of ERK1/2 was used for these latter studies because it is a measure of several convergent pathways including G protein-dependent (G␣ q and G␣ i/o ) and G protein-independent signaling events, and it is also responsible for cell differentiation after CaSR activation (58) .
A number of interesting findings arose from these experiments. At the WT CaSR, Ca (Fig. 4, B-D) , although changes in Ca 2ϩ o potency were, in general, smaller in ERK1/2 phosphorylation assays (Table 3 ). For the A 843 E mutant, an increase in basal ERK1/2 phosphorylation was observed, consistent with constitutive activity observed in IP accumulation assays and as reported previously (14, 15) .
Finally, three mutants showed differences in their impact on maximal responses in Ca 2ϩ i mobilization and ERK1/2 phosphorylation assays. In the case of L 727 Q and V 836 L, the maximum response was significantly reduced (P Ͻ 0.05) in Ca 2ϩ i mobilization assays, but not in ERK1/2 phosphorylation assays (Fig. 4E) . For G i mobilization assays was due to pathway desensitization. In IP accumulation assays, an alternative measure of G ␣ q signaling, the maximum response of A 843 E was similar to the WT CaSR (Supplemental Fig. 3) .
Taken together, the data indicate that mutations in the HHD and ECL of the CaSR induce pathway-selective bias that favors the preferential activation (gain of function) or inhibition (loss of function) of one signaling pathway over another. This is particularly apparent for the majority of gain-of-function mutants. Although the WT CaSR and the majority of mutant receptors couple more strongly to Ca 2ϩ i mobilization than ERK1/2 phosphorylation, at the 
Discussion
In this study we sought to determine the impact of a set of naturally occurring and clinically relevant mutations located predominantly in the HHD and ECL of the human CaSR on signaling pathway bias. By characterizing the pharmacological consequences of these clinically relevant mutations, we have identified various mutation-induced impairments involving changes in receptor expression as well as basal and/or agonist-stimulated signaling responses via two distinct pathways, Ca Diverse mutant phenotypes that exhibited one of the following profiles were identified: selective loss of expression, selective loss of function, combined loss of expression with loss of function, combined loss of expression with gain of function, selective gain of function, combined gain of function with reduced signaling capacity and, finally, constitutive activity. Importantly, disturbances in agonist signaling led to the identification of naturally occurring mutations that induce biased signaling by shifting the balance of coupling between the two pathways. This finding has important implications for the treatment of disorders of Ca 2ϩ o metabolism associated with CaSR mutations. The results also have more general implications for disorders arising from mutations in other GPCR.
Detailed knowledge of the effects of mutations on the pharmacological properties of the CaSR affords the possibility of designing drugs that specifically target the molecular determinant of impairment. Drugs that act to pharmacochaperone selectively impaired loss-of-expression receptors to the cell surface without altering their sensitivities to agonists or endogenous modulators provide one example. Drugs that selectively restore Ca 2ϩ i mobilization or ERK1/2 phosphorylation according to the specific signaling impairment of mutant receptors provide another example. Furthermore, the majority of patients that present with mild to moderate elevations in serum Ca 2ϩ o , as observed in FHH, are heterozygous for CaSR mutations, whereas NSHPT is caused, in general, by homozygous mutations (with the exception of the dominant-negative mutant, R 185 Q). Thus, drugs that specifically modulate the mutated receptor while having no effect on the WT CaSR, or drugs that differentially modulate the mutantmutant vs. mutant-WT CaSR dimer may also be desirable.
The results demonstrate that the WT CaSR couples more strongly to Ca 2ϩ i mobilization than ERK1/2 phosphorylation and that certain mutations alter this preference, as seen in the bias plots shown in Fig. 5 . Thus, with respect to PTH secretion and Ca agonist-stimulated ERK1/2 phosphorylation (25). Similarly, for the majority of gain-of-function mutants studied herein, alterations in agonist potency were either small or not observed in ERK1/2 phosphorylation assays, whereas Ca 2ϩ o potency was significantly enhanced (P Ͻ 0.05) in Ca 2ϩ i mobilization assays. Thus, a drug that negatively and selectively modulates this latter pathway may be clinically desirable.
For some gain-of-function mutants, we noted a reduction in the maximum signaling response to Ca 2ϩ o in Ca 2ϩ i mobilization assays. In the case of A 843 E, this was clearly attributed to enhanced pathway desensitization through depletion of Ca 2ϩ i stores rather than reduced surface expression or reduced intrinsic signaling capacity, highlighting an additional pharmacological property that may be targeted therapeutically. At the level of desensitization of the receptor itself, protein kinase C phosphorylation inhibits coupling of the CaSR to Ca 2ϩ i mobilization (59) , and a naturally occurring mutation at a key protein kinase C phosphorylation site, T 888 M, which prevents phosphorylation at this residue, results in enhanced receptor signaling and hypocalcemia (60, 61) , indicating that a fine balance between phosphorylation and dephosphorylation events plays a critical role in regulating agonist-mediated signaling. With respect to the control of cell surface receptor density, the CaSR is endocytosed and targeted to the lysosome for degradation in an agonist-independent manner (62) . Hence, mutations that alter CaSR desensitization do so in a manner that may not always reflect traditional concepts of agonist-induced GPCR internalization. In addition, exposure of cell surface CaSR to agonists has recently been reported to stimulate recruitment of intracellular receptors to the plasma membrane (62) . It may therefore be therapeutically beneficial to target binding sites that modulate processes linked to insertion of receptors into the plasma membrane, rates of T 888 phosphorylation or dephosphorylation, and various other processes that regulate trafficking and signal pathway selection.
In the current study we also identified residues essential for receptor expression and function. The identification of residues that support intrinsic receptor activation highlights motifs involved in the transmission of the activation signal from the Ca In conclusion, the current study demonstrates how disorders of Ca 2ϩ o homeostasis due to mutations in the human CaSR may be attributed to a number of distinct pharmacological disturbances that manifest as alterations in the level of cell surface expression and modification of both basal and agonist-stimulated coupling to signaling pathways. Importantly, changes in receptor function do not simply reflect a universal switch between lower or higher intrinsic activity across all pathways. Instead, CaSR mutations induce conformational changes that differentially disturb receptor coupling to downstream pathways. Thus, much like the concept of ligand-directed signaling or biased agonism (24, 65) , whereby different ligands stabilize unique receptor conformations, mutations in the CaSR can induce signaling bias by stabilizing receptor conformations that couple differentially to intracellular signaling pathways. This is particularly pertinent for understanding how mutations alter the function of GPCR, and biased signaling must thus be considered in both a biological and therapeutic setting because it has important implications for the design of drugs that specifically target clinically relevant GPCR-coupled signaling pathways.
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